ConductScience.org, home

Paper359336

The macrophage, target cell of the synthetic adjuvant muramyl dipeptide.

Fevrier M and 4 others. Eur J Immunol, 1978. Cited by 101 papers, by iCite.

Cite this record

ConductScience Library. The macrophage, target cell of the synthetic adjuvant muramyl dipeptide. Papers, record 359336. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/359336

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The macrophage, target cell of the synthetic adjuvant muramyl dipeptide.
PubMed
Journal
Eur J Immunol
PubMed
Year
1978
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
101
iCite
Relative citation ratio, by iCite
2.78
iCite
Revised in PubMed
2003-11-14
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Fevrier MM
2Birrien JLJ L
3Leclerc CC
4Chedid LL
5Liacopoulos PP

Source PubMed

Download CSV of authors

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Acetylmuramyl-Alanyl-IsoglutamineMajor topic
Adjuvants, ImmunologicMajor topic
GlycopeptidesMajor topic
MacrophagesMajor topic
Animals
Antigens
Cells, Cultured
Erythrocytes
Hemolytic Plaque Technique
Male
Mice
Mice, Inbred C57BL
Mice, Inbred DBA
Muramic Acids
Polysaccharides, Bacterial
Sheep
Spleen

Source PubMed

Download CSV of topics

Cited by21

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 101 citations.

PMIDTitleJournalYearIn PapersSource
36848790Highlights into historical and current immune interventions for cancer.Int Immunopharmacol2023https://conductscience.org/library/papers/36848790PubMed
36013944Regulation of Immune Homeostasis via Muramyl Peptides-Low Molecular Weight Bioregulators of Bacterial Origin.Microorganisms2022https://conductscience.org/library/papers/36013944PubMed
28026115Immune Cell-Mediated Biodegradable Theranostic Nanoparticles for Melanoma Targeting and Drug Delivery.Small2017https://conductscience.org/library/papers/28026115PubMed
26565602Roles and relevance of mast cells in infection and vaccination.J Biomed Res2016https://conductscience.org/library/papers/26565602PubMed
17422948Adjuvants et stimulants de l'immunité: propriétés immunorégulatrices du muramyl-dipeptide, des corynébactéries anaérobies et du diéthyldithiocarbamate de sodium.Can Vet J1988https://conductscience.org/library/papers/17422948PubMed
7439991Effects of treatment with muramyl dipeptide and certain of its analogs on resistance to Listeria monocytogenes in mice.Infect Immun1980https://conductscience.org/library/papers/7439991PubMed
7216470Effects of muramyl dipeptide treatment on resistance to infection with Toxoplasma gondii in mice.Infect Immun1981https://conductscience.org/library/papers/7216470PubMed
7061099Regulation of secondary antibody responses in rodents. II. The requirement for continued antigen supply to maintain IgG production.Immunology1982https://conductscience.org/library/papers/7061099PubMed
7035868Muramyl peptides. Chemical structure, biological activity and mechanism of action.Mol Cell Biochem1981https://conductscience.org/library/papers/7035868PubMed
6982864In vitro studies on the adjuvanticity of Brucella fractions.Infect Immun1982https://conductscience.org/library/papers/6982864PubMed
6979042In vivo immune response to a T-cell-dependent antigen by cultures of disassociated murine Peyer's patch.Proc Natl Acad Sci U S A1982https://conductscience.org/library/papers/6979042PubMed
6840853Effective immunity to dental caries: enhancement of salivary anti-Streptococcus mutans antibody responses with oral adjuvants.Infect Immun1983https://conductscience.org/library/papers/6840853PubMed
6767407Epithelioid granuloma formation by a synthetic bacterial cell wall component, muramyl dipeptide (MDP).Am J Pathol1980https://conductscience.org/library/papers/6767407PubMed
6743532Enhancement of the local inflammatory response to bacterial infection by muramyl dipeptide.Br J Exp Pathol1984https://conductscience.org/library/papers/6743532PubMed
6437984Processing of Bacillus subtilis peptidoglycan by a mouse macrophage cell line.Infect Immun1984https://conductscience.org/library/papers/6437984PubMed
6334022Accelerated expansion of antibody heterogeneity by complete Freund's adjuvant during the response to bacterial alpha-amylase.Immunology1984https://conductscience.org/library/papers/6334022PubMed
6187686Enhancement of antigen-specific suppression by muramyl dipeptide.Infect Immun1983https://conductscience.org/library/papers/6187686PubMed
3988341Synergistic effect of glucantime and a liposome-encapsulated muramyl dipeptide analog in therapy of experimental visceral leishmaniasis.Infect Immun1985https://conductscience.org/library/papers/3988341PubMed
2187809Containment as a mechanism of nonspecific enhancement of defenses against bacterial infection.Infect Immun1990https://conductscience.org/library/papers/2187809PubMed
478648Macrophage activation by bacterial cell walls and related synthetic compounds.Infect Immun1979https://conductscience.org/library/papers/478648PubMed

See all 21 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/359336

GET https://conductscience.org/api/papers/v1/359336/cited_by?page=2